The agreement gives the life science company the rights to use Selexis’ cell line, generated using their SUREtechnology Platform.
The Australia-based firm did not disclose which antibody they will make, saying only that they will create it using cGMP (current good manufacturing practices) production quality processes.
The financial terms of the agreement were not disclosed.
Igor Fisch, CEO at Selexis, said: “We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform.
"This agreement represents Selexis' commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL."